Evidence mapPaperPMID 27699406Full record

ReviewInvestigative ophthalmology & visual science2016

Report From the NEI/FDA Diabetic Retinopathy Clinical Trial Design and Endpoints Workshop.

Prashant Nair, Lloyd Paul Aiello, Thomas W Gardner, Lee M Jampol, Frederick L Ferris

Abstract readReview
In one paragraph

Review in Investigative ophthalmology & visual science, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Article
  4. Review
  5. Diabetic retinal disease.Nature reviews. Disease primers · 2025
    Review
  6. Article
  7. Photoreceptor layer elevation due to subretinal fluid: Impact on visual acuity measurements and simulation from biometrics.Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists) · 2025
    Article
  8. Article
  9. Frontiers in diabetic retinal disease.Journal of diabetes and its complications · 2023
    Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Looking Ahead: Visual and Anatomical Endpoints in Future Trials of Diabetic Macular Ischemia.Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde · 2021
    Review
  15. Clinical Perspectives and Trends: Microperimetry as a Trial Endpoint in Retinal Disease.Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde · 2021
    Review
  16. Review
  17. Test-retest repeatability of the pattern electroretinogram and flicker electroretinogram.Documenta ophthalmologica. Advances in ophthalmology · 2019
    Article
  18. The role of inflammation in diabetic eye disease.Seminars in immunopathology · 2019
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Prashant NairWashington, DC, United States.
Lloyd Paul AielloJoslin Diabetes Center, Boston, Massachusetts, United States.
Thomas W GardnerUniversity of Michigan, Ann Arbor, Michigan, United States.
Lee M JampolNorthwestern University, Chicago, Illinois, United States.
Frederick L FerrisNational Eye Institute, Bethesda, Maryland, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

National Eye Institute (U.S.)United States Food and Drug AdministrationClinical Trials as TopicCongresses as TopicDiabetic RetinopathyHumansUnited States

Identifiers

PMID27699406
PMCPMC6016432

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.